Are ultrasound features at the first metatarsophalangeal joint associated with clinically-assessed pain and function? A study of people with gout, asymptomatic hyperuricaemia and normouricaemia

Sarah Stewart 1*, Nicola Dalbeth 2,3, Alain C. Vandal 4,5, Bruce Allen 6, Rhian Miranda 7 and Keith Rome 1

Abstract

Background: The first metatarsophalangeal joint (1st MTP joint) is a common location for sonographic evidence of urate deposition in people with gout and asymptomatic hyperuricaemia. However, it is unclear whether these are related to clinically-assessed pain and function. This study aimed to determine the association between ultrasound features and clinical characteristics of the 1st MTP joint in people with gout, asymptomatic hyperuricaemia and age- and sex-matched normouricaemic individuals.

Methods: Twenty-three people with gout, 29 with asymptomatic hyperuricaemia and 34 with normouricaemia participated in a cross-sectional study. No participant had clinical evidence of acute inflammatory arthritis at the time of assessment. Four sonographic features at the 1st MTP joint were analysed: double contour sign, tophus, bone erosion and synovitis. Clinical characteristics included in the analysis were 1st MTP joint pain, overall foot pain and disability, 1st MTP joint temperature, 1st MTP joint range of motion and gait velocity. Statistical analyses adjusted for the diagnostic group of the participant.

Results: After accounting for the diagnostic group, double contour sign was associated with higher foot pain and disability scores (P < 0.001). Ultrasound tophus was associated with higher foot pain and disability scores (P < 0.001), increased temperature (P = 0.005), and reduced walking velocity (P = 0.001). No associations were observed between ultrasound synovitis or erosion and the clinical characteristics.

Conclusions: Ultrasound features of urate crystal deposition, rather than soft tissue inflammation or bone erosion, are associated with clinical measures of foot-related functional impairment and disability even in the absence of clinical evidence of current acute inflammatory arthritis. This association persisted regardless of the diagnosis of the participant as having gout or asymptomatic hyperuricaemia.

Keywords: Gout, Foot, Hyperuricemia, Ultrasonography
Background
Musculoskeletal ultrasonography has gained notable recognition among imaging modalities used in the assessment of gouty arthritis due to its ability to visualise not only soft tissue inflammation and joint damage, but also monosodium urate (MSU) crystals. Recent sonographic studies have demonstrated MSU deposition and inflammation within musculoskeletal structures in patients with gout even in the absence of current symptoms of acute arthritis [1–3]. Furthermore, hyperuricaemic individuals, who have never experienced an episode of acute foot arthritis, also demonstrate subclinical deposition of MSU crystals on ultrasound assessment [4–7]. The long-term relevance of ongoing subclinical disease activity in these individuals is uncertain.

MSU crystal deposition primarily targets peripheral structures of the lower limbs and individuals with both gout and asymptomatic hyperuricaemia present with high levels of self-reported foot pain and disability when compared to healthy people with normal urate levels [8]. Biomechanical-based research has also shown that they demonstrate lower limb functional impairments related to spatiotemporal parameters of gait and plantar foot loading [9–11].

The first metatarsophalangeal joint (1st MTP joint), which plays an important functional role during the propulsive phase of gait, is the most common joint affected in people with gout. A recent meta-analysis estimated 73% of people with gout experience symptoms of acute arthritis at the 1st MTP joint at least once during the course of their disease [12]. In addition, patients with gout report persistent 1st MTP joint pain and exhibit local structural and functional changes at this joint including reduced muscular strength, limited joint motion and an increased prevalence of musculoskeletal deformity [8].

Associations have been shown between imaging findings and clinical measures of foot pain and function in people with rheumatoid arthritis [13] and people without arthritis with painful 1st MTP joints [14]. However, it is unclear whether 1st MTP joint sonographic features are related to clinical measures of structure, function and pain in people with gout or asymptomatic hyperuricaemia, despite the important functional role of this joint and its susceptibility to MSU deposition. This study aimed to determine the association between sonographic features and clinical characteristics of the 1st MTP joint in people with gout, asymptomatic hyperuricaemia and age- and sex-matched normouricaemic individuals.

Methods
We analysed data from a cross-sectional study examining both ultrasound features and foot function in people with gout, asymptomatic hyperuricaemia, and age- and sex-matched normouricaemic controls [1, 8, 9]. This analysis of the association between ultrasound findings and foot pain and function was pre-specified in the study protocol.

Participants
Ethical approval for the study was obtained from the AUT Ethics Committee (13/100). All participants provided written informed consent prior to data collection. A total of 86 participants (gout n = 23, asymptomatic hyperuricaemia n = 29, and age- and sex-matched normouricaemic controls n = 34) were included in the study. This sample size was calculated from existing prevalence rates of the double contour sign at the 1st MTP joint [2, 5, 15–17], which provides approximately 80% power to detect a difference between asymptomatic hyperuricaemia and controls and 87% power to detect a difference between gout and controls at a significance level of 5% against two-side alternatives. Participants with gout were recruited from Auckland District Health Board, New Zealand, using a consecutive sampling technique. All participants with gout fulfilled the 1977 preliminary American Rheumatism Association (ARA) classification criteria for gout [18]. Participants without gout were recruited from Auckland University of Technology (AUT) staff and underwent serum urate capillary testing on the day of the study using a Reflotron® Plus (Roche Diagnostics Ltd., New Zealand). They were stratified into either the asymptomatic hyperuricaemic group (serum urate ≥ 6.9 mg/dL) or the normouricaemic control group (serum urate < 6.9 mg/dL). The three groups were age-and sex-matched. Participants were excluded if they were aged under 20 years (to meet the requirements of the AUT Ethics Committee); had a history of other inflammatory arthritis; were experiencing acute arthritis at the time of the study; had foot and/or ankle surgery in the previous three months; had a history of 1st MTP joint surgery; or lower limb amputation. Demographic data were obtained from all participants including age, gender, ethnicity, body mass index (BMI), current medications and medical history. Additionally, gout disease characteristics were documented for participants with gout including disease duration, flare history and tophus presence.

Sonographic features
The ultrasound examination was performed at the AUT Horizon Scanning Clinic by a single experienced musculoskeletal radiologist (BA) who was blinded to all clinical features including gout status and serum urate results. A Phillips iU22 diagnostic ultrasound machine (Bothell, Washington, USA) with a 10 MHz, 55 mm linear array transducer was used. All B-mode settings, including frequency, focal zones, gain and depth were standardised across participants. Bilateral 1st MTP joints were scanned with participants positioned supine with legs extended. A water-based gel was applied to the skin to optimise transducer-skin contact and to provide an acoustic interface. The dorsal, medial and plantar aspects of each joint were scanned using a multi-planar technique, in which
transverse and longitudinal planes were imaged. Each joint was maximally dorsiflexed and plantarflexed by the radiologist during scanning to ensure direct visualisation of the articular surface of the first metatarsal head. A dynamic technique was adopted in which the probe insonation angle was manipulated by the sonographer to reduce the occurrence of the cartilage interface sign. Each joint was scanned in B-mode grey scale and then using power Doppler. Power Doppler involved the use of a standardised pulse repetition frequency of 400 to 500 Hz and low wall filters with the gain adjusted to a level just below the disappearance of the colour signs within the bony cortex [19, 20].

Two musculoskeletal radiologists (BA and RM) who were blinded to all clinical features, including diagnostic group status and serum urate results, and to each other’s scores, independently reviewed the static images for the presence of four ultrasound features: the double contour sign, tophus, erosion and synovitis. The double contour sign was defined as an abnormal hyperechoic band over the superficial margin of the articular cartilage, independent of insonation [21]. Tophus was defined as a circumscribed, inhomogeneous, hyperechoic and/or hypoechoic aggregation that may or may not generate a posterior acoustic shadow and that may be surrounded by a small anechoic rim [21]. Erosions were defined as intra-articular discontinuity of the bone surface, visible in two perpendicular planes [21]. Synovitis was defined as the presence of the power Doppler signal (including both single and confluent vessel signals) within the joint space [22]. For the purpose of the inferential analyses, ultrasound features were considered present only if scored as present by both readers.

Clinical foot assessment
Both right and left 1st MTP joint pain over the past week was assessed using 100 mm Visual Analogue Scales (VAS) anchored with ‘no pain’ (0 mm) and ‘worst pain imaginable’ (100 mm). Patient-reported overall foot pain was assessed using the 19-item Manchester Foot Pain and Disability Index (MFPDI) [23]. Each item was answered ‘none of the time’ (scored as 0), ‘on some days’ (scored as 1) or ‘on most/every day(s)’ (scored as 2) in the past month and a total score out of 38 was summated for each participant.

Temperature of the 1st MTP joint was measured using a DermaTemp 1001 (Exergen Corporation, Massachusetts), which is a hand-held infrared thermographic scanner with an in-built sensor. Participants were given adequate equilibration time in the room (thermostatically controlled at 22 °C ± 2 °C). Three temperature readings were recorded from the dorsal aspect of the 1st MTP joint for each foot, and the mean of the three trials calculated for use in the inferential analyses.

Passive, non-weight-bearing 1st MTP joint dorsiflexion range of motion (ROM) was measured using a hand-held goniometer (Whitehall Manufacturing Ltd., California, USA) in accordance with the procedure outlined by Hopson and McPoil [24]. Participants were positioned seated with knees extended and the ankle in neutral. Lines were drawn on the medial aspect of the foot along the sagittal bissections of the first metatarsal and proximal phalanx. The examiner applied a dorsiflexion force to the hallux until it could no longer be passively moved into further extension. The angle between the two bisection lines was measured from the goniometer. Three repeated measurements of right and left feet were taken and the mean for each foot calculated for use in the inferential analyses.

Walking velocity (m/s) during level barefoot walking was collected using the GAITRite system (CIR Systems, Inc., New Jersey, US). The GAITRite is a 700 cm x 90 cm electronic walkway with an active sensor area of 610 cm long and 60 cm wide. The active area contains 23,040 embedded pressure-activated sensors with a spatial resolution of 1.27 cm and a sampling rate of 120 Hz. All data was processed and stored by an IBM compatible computer using GAITRite® gold, Version 3.2 b software. Participants were instructed to walk at their own comfortable walking speed [25] from a point 100 cm before the walkway and finishing 100 cm past its end to ensure that when they reached the walkway they were walking at a normal speed and momentum. Three trials of barefoot walking were recorded for each participant with adequate rest time between trials and the mean of the three trials used for the inferential analyses.

Statistical analysis
All descriptive data were described as mean (SD) for continuous data and frequency (%) for categorical data. All clinical outcome measures were reviewed for normality using the residuals from a linear model. Mixed linear regression models were used to determine the univariate associations between the sonographic features (independent variables) and clinical characteristics (dependent variables) of the 1st MTP joint. The overall models included the sonographic feature as a fixed effect as well as the interaction effect between the sonographic feature and diagnostic group. All models accounted for repeated measures taken from right and left feet through inclusion of a participant-specific random effect and participant-nested random effect for foot-side were added to the model. This analysis produces results identical to an analysis of measures averaged for each foot-side that would allow for a between-foot-side correlation and also allows for any reweighting required due to missing values. Bonferroni-adjusted significance levels were used for the inferential analyses (P < 0.01). Data were analysed using IBM SPSS Statistics version 22.
### Table 1 Descriptive statistics for participant, sonographic and clinical characteristics

| Variable                                      | Control | Gout | Asymptomatic hyperuricaemia |
|-----------------------------------------------|---------|------|----------------------------|
| N                                             | 34      | 23   | 29                         |
| Gender, male, n (%)                           | 34 (100)| 23 (100)| 29 (100)                   |
| Age, years                                    | 58 (14) | 58 (14)| 58 (19)                    |
| Ethnicity, n (%)                              |         |      |                            |
| European                                     | 30 (88) | 14 (61)| 24 (83)                    |
| Maori                                         | 1 (3)   | 1 (4) | 0 (0)                      |
| Pacific                                       | 0 (0)   | 4 (17)| 3 (10)                     |
| Asian                                         | 3 (9)   | 17 (17)| 2 (7)                      |
| BMI, kg/m²                                     | 25.0 (2.9) | 30.8 (3.8)* | 29.3 (5.9)* |
| Diuretic use, n (%)                           | 4 (12)  | 3 (13) | 7 (24)                      |
| NSAID use, n (%)                              | 7 (21)  | 14 (61)*| 11 (38)                    |
| Prednisone use, n (%)                         | 0 (0)   | 5 (22) | 0 (0)                      |
| Hypertension, n (%)                           | 9 (26)  | 16 (70)*| 16 (55)*                    |
| Cardiovascular disease, n (%)                 | 1 (3)   | 6 (26)*| 5 (17)                      |
| Diabetes, n (%)                               | 2 (6)   | 4 (17) | 1 (3)                      |
| Serum urate, mg/dl                            | 5.4 (1.0) | 5.9 (1.7) | 7.7 (0.8)*                |
| Disease duration, years                       | -       | 18 (11) | -                          |
| Number of acute flares in preceding 3 months | -       | 1.4 (1.4)| -                          |
| 1MTP flares in preceding 3 months, n (%)     | -       | 6 (26) | -                          |
| History of 1st MTP joint flares, n (%)        | -       | 19 (83) | -                          |
| Presence of clinically-evident tophi at any site, n (%) | - | 17 (74) | -                          |
| Presence of clinically-evident tophi at the 1st MTP joint, n (%) | - | 6 (13) | -                          |
| Urate lowering therapy, n (%)                 | -       | 22 (96) | -                          |
| Microscopically-proven gout, n (%)            | -       | 6 (26) | -                          |
| US double contour sign, n (%)                 | 9 (13)  | 17 (37) | 21 (36)                    |
| US tophus, n (%)                              | 0 (0)   | 6 (13) | 0 (0)                      |
| US erosion, n (%)                             | 2 (3)   | 15 (33) | 1 (2)                      |
| US synovitis, n (%)                           | 5 (7)   | 20 (44) | 2 (3)                      |
| 1st MTP joint pain VAS, mm                    | 1.6 (4.0) | 8.5 (15.6) | 6.9 (15.1)                |
| Manchester Foot Pain and Disability Index     | 1.8 (6.0) | 13.4 (10.8) | 3.4 (4.8)                |
| 1st MTP joint range of motion, °              | 77.6 (17.4) | 59.0 (19.6) | 76.5 (16.9)          |
| 1st MTP joint temperature, °C                 | 25.3 (2.1) | 27.4 (2.8) | 26.1 (2.2)                |
| Gait velocity, m/s                            | 1.05 (0.19) | 0.88 (0.17) | 1.05 (0.24)          |

Values presented as mean (SD) unless otherwise indicated. *Significantly different from control group (P < 0.05). †Values are based on joints (controls = 68 joints; gout = 46 joints; asymptomatic hyperuricaemia = 58 joints). BMI body mass index, NSAID non-steroidal anti-inflammatory drugs, US ultrasound, VAS Visual Analogue Scale, °C degrees.

### Table 2 Association between clinical characteristics and presence of the double contour sign

|                          | Least squares mean Diff. 95% CI for Diff. | P       |
|--------------------------|-------------------------------------------|---------|
|                          | Present | Absent | Lower | Upper |        |
| 1st MTP joint Pain VAS, mm | 3.4     | 7.0    | 3.5   | −1.0  | 8.0    | 0.12   |
| Manchester Foot Pain and Disability Index | 10.1    | 4.8    | −5.4  | −7.8  | −2.9   | <0.001*|
| 1st MTP joint range of motion, ° | 68.8    | 72.2   | 2.4   | −3.2  | 8.1    | 0.40   |
| 1st MTP joint temperature, °C | 26.8    | 26.0   | −0.8  | −1.5  | 0.1    | 0.018  |
| Walking velocity, m/s | 1.02    | 1.00   | −0.02 | −0.10 | 0.05   | 0.52   |

Results are presented adjusted for diagnostic group. *Significantly different at Bonferroni-adjusted level of <0.01. Diff. Difference in mean estimate between presence and absence, CI Confidence Interval, 1st MTP joint first metatarsophalangeal joint, °C degrees.
Results

All participants were men with a mean age of 58 years and predominantly of European ethnicity (Table 1). Participants with gout and asymptomatic hyperuricaemia had significantly higher BMI compared to the controls ($P < 0.05$). Participants with gout had a mean (SD) disease duration of 18 (11) years. Eighty-three percent had a history of 1st MTP joint acute arthritis and 26% had clinical evidence of 1st MTP joint tophi. Descriptive statistics for the ultrasound features and clinical characteristics are also presented in Table 1.

The distribution of residuals from the linear models for all continuous outcome measures demonstrated sufficient normality to carry out parametric testing. The interaction effect between the sonographic feature and diagnostic group was significant ($P < 0.05$) in the majority of analyses (data not reported), indicating that associations between the ultrasound and clinical variables were different across groups. After accounting for the diagnostic group, presence of the double contour sign was significantly associated with higher MFPDI scores ($P < 0.001$) (Table 2). After accounting for the diagnostic group presence of tophus was significantly associated with higher MFPDI scores ($P < 0.001$), increased 1st MTP joint temperature ($P = 0.005$) and reduced walking velocity ($P = 0.001$) (Table 3). No associations were observed between erosion and the clinical characteristics (Table 4) or synovitis and the clinical characteristics (Table 5).

Discussion

This study sought to identify the association between sonographic features of urate deposition, bone erosion and soft tissue inflammation at the 1st MTP joint and clinically-assessed outcomes related to pain, structure and function of the 1st MTP joint while accounting for the diagnosis of the participant as having gout, asymptomatic hyperuricaemia or normouricaemia.

Both sonographic features of MSU deposition, double contour sign and tophus, were associated with increased overall patient-reported foot pain and disability. Previous research has shown that pain and functional limitations related to the feet and lower limbs are a persistent finding in people with gout and asymptomatic hyperuricaemia, even in the absence of acute arthritis [8, 26, 27]. Our findings indicate that urate deposition, rather than soft tissue or bone changes, may be associated with foot-related pain and disability. The lack of association between the double contour sign and other clinical characteristics may be related to the overall low prevalence of the double contour sign in the participants. This may be related to difficulty in differentiating this sign from the normal cartilage interface reflection in addition to the moderate inter-observer reliability [1].

The presence of tophus at the 1st MTP joint was also associated with increased local temperature, which is a clinical feature of underlying inflammation. The presence of larger urate deposits, in the form of tophi, may represent a more progressive disease and an environment more

| Table 3 | Association between clinical characteristics and presence of tophus |
|----------------|-----------------|---------------|-----------------|-----------------|
|               | Least squares mean | Diff. | 95% CI for Diff. | $P$               |
|               | Present | Absent |               | Lower | Upper |               |
| 1st MTP joint Pain VAS, mm | 2.4   | 6.0   | 3.6            | −7.0  | 14.3  | 0.50           |
| Manchester Foot Pain and Disability Index | 19.8  | 5.9   | −13.9          | −19.7 | −8.1  | <0.001*        |
| 1st MTP joint range of motion, ° | 55.1  | 71.2  | 16.1           | 2.4   | 29.7  | 0.021          |
| 1st MTP joint temperature, °C | 28.6  | 26.2  | −2.3           | −3.9  | −0.7  | 0.005*         |
| Walking velocity, m/s | 0.88  | 1.00  | 0.11           | 0.05  | 0.18  | 0.001*         |

Results are presented adjusted for diagnostic group. *Significantly different at Bonferroni-adjusted level of $<0.01$. Diff. Difference in mean estimate between presence and absence, CI Confidence Interval, 1st MTP joint first metatarsophalangeal joint, ° degrees

| Table 4 | Association between clinical characteristics and presence of erosion |
|----------------|-----------------|---------------|-----------------|-----------------|
|               | Least squares mean | Diff. | 95% CI for Diff. | $P$               |
|               | Present | Absent |               | Lower | Upper |               |
| 1st MTP joint Pain VAS, mm | 3.1   | 6.3   | 3.2            | −6.0  | 12.4  | 0.49           |
| Manchester Foot Pain and Disability Index | 6.6   | 5.6   | −1.0           | −6.9  | 4.9   | 0.75           |
| 1st MTP joint range of motion, ° | 66.2  | 71.2  | 5.0            | −4.8  | 14.8  | 0.32           |
| 1st MTP joint temperature, °C | 25.1  | 26.2  | 1.1            | 0.1   | 2.1   | 0.040          |
| Walking velocity, m/s | 0.95  | 1.00  | 0.05           | −0.11 | 0.21  | 0.53           |

Results are presented adjusted for diagnostic group. Diff. Difference in mean estimate between presence and absence, CI Confidence Interval, 1st MTP joint first metatarsophalangeal joint, ° degrees
prone to chronic inflammation, and therefore increased temperature, as a result of continuous mechanical stress in the joint during gait. In contrast, no relationship was observed between synovitis (a direct measure of increased soft tissue vascularisation) and increased temperature. It may be that participants with synovitis in the current study had only a mild Doppler signal [1], which may not have been severe enough to be seen in clinical thermal variations. It may be that the relationship between synovitis and temperature would be more pronounced in patients experiencing current acute flares, who experience a higher prevalence of more prominent Doppler signal [28]. This is consistent with studies in rheumatoid arthritis, which have detected sonographic evidence of synovitis despite the absence of any clinical features of inflammation [29–32].

The reduction in walking velocity in those with 1st MTP joint tophus may be a result of the inability to achieve the required 65° of dorsiflexion at the joint necessary for efficient propulsion in combination with reduced 1st MTP joint plantarflexion strength and foot pain [8]. This may support previously proposed hypotheses that altered walking patterns adopted by people with gout are related to pain-avoidance strategies and inefficient 1st MTP joint function [9–11].

The findings from this study should be considered in light of a number of limitations. Firstly, recruitment of participants was undertaken prior to publication of the 2015 ACR/EULAR classification criteria for gout [33] and the majority of the participants with gout were classified based on the 1977 ACR clinical criteria, which has limited specificity [34]. Participants with normouricaemia and hyperuricaemia were classified based on a single measure of serum urate, which may have reduced accuracy compared with multiple measurements over a longer time period. The sampling technique used in the current study resulted in all male participants, meaning the results may not be generalisable to both genders. The adoption of a higher frequency transducer during scanning may have enhanced the ultrasound findings. The cross-sectional design of the study limits the ability to determine whether sonographic features at the 1st MTP joint preceded or were a consequence of the clinical characteristics. Finally, concomitant osteoarthritis, which was not assessed in the current study, is highly prevalent at the 1MTP in people with gout [35], and may contribute to their functional impairment and disability. The current study was limited to sonographic assessment of the 1st MTP joint, and further assessment of other foot and ankle structures for urate deposition, soft tissue and osseous changes, may provide further insight into the impact of sonographic features on overall foot-related pain and disability. Additionally, further longitudinal research may explore the role of foot and ankle structure and function in predicting crystal deposition, inflammation and osseous erosion in individuals with asymptomatic hyperuricaemia.

### Conclusions

In conclusion, this study has shown that sonographic features of MSU deposition, rather than soft tissue inflammation or bone erosion, are associated with clinically evident foot-related pain, impairment and functional disability. This may explain why these individuals with asymptomatic hyperuricaemia, who lacked sonographic features of soft tissue and bone involvement at the 1st MTP joint [1], still presented with high levels of foot pain and disability [8] and exhibited gait impairments [9] when compared with normouricaemic individuals.

### Abbreviations

- 1st MTP joint: first metatarsophalangeal joint
- ARA: American Rheumatism Association
- AUT: Auckland University of Technology
- BMI: body mass index
- MFPDI: Manchester foot pain and disability index
- MSU: monosodium urate
- ROM: range of motion
- VAS: visual analogue scale

### Acknowledgements

None.

### Funding

This study was funded by Arthritis New Zealand.

### Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

---

### Table 5: Association between clinical characteristics and presence of synovitis

|                        | Least squares mean | Diff. | 95% CI for Diff. | P     |
|------------------------|--------------------|-------|-----------------|-------|
|                        | Present | Absent |                  | Lower | Upper |     |
| 1st MTP joint Pain VAS, mm | 5.7     | 5.7               | 0.0               | -6.7  | 6.8   | 0.99 |
| Manchester Foot Pain and Disability Index | 8.4     | 5.8                    | -2.7               | -6.9  | 1.6   | 0.21 |
| 1st MTP joint range of motion, ° | 66.3    | 71                     | 4.7                | -2.5  | 12.0  | 0.20 |
| 1st MTP joint temperature, °C | 26.8    | 26.2                  | -0.6               | -1.4  | 0.2   | 0.13 |
| Walking velocity, m/s | 0.94    | 1.01                  | 0.07               | -0.06 | 0.19  | 0.29 |

Results are presented adjusted for diagnostic group. Diff. Difference in mean estimate between presence and absence, CI Confidence interval, 1st MTP joint first metatarsophalangeal joint, ° degrees.
Author’s contributions
SS made substantial contributions to conception and design of the study, undertook all clinical data collection, contributed to analysis and interpretation of data and to writing the manuscript. ND made substantial contributions to conception and design, to interpretation of data and to writing the manuscript. AV made substantial contribution to the conception and design of the study, analysis and interpretation of the data and to writing the manuscript. BA and RM undertook all sonographic data collection, contributed to the interpretation of the data and to writing of the manuscript. KR made substantial contributions to conception and design, to interpretation of data and to writing the manuscript. All authors were involved in drafting of the manuscript or revising it critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests
ND has received personal fees or grants from Takeda, Teijin, Menarini, Pfizer, AstraZeneca, Ardea, Crealta, Cymbay, and Fonterra. The other authors declare no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Auckland University of Technology Ethics Committee (13/100). All participants provided written informed consent.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Podiatry, Health & Rehabilitation Research Institute, Auckland University of Technology, Private Bag 92006, Auckland, 1142, New Zealand. 2 Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. 3 Department of Rheumatology, Auckland District Health Board, P.O. Box 92189, Auckland, New Zealand. 4 Department of Biostatistics & Epidemiology, Faculty of Health and Environmental Sciences, Auckland University of Technology, Private Bag 92006, Auckland 1142, New Zealand. 5 Health Intelligence & Informatics, Ko Awatea, Counties Manukau Health, Private Bag 93311, Auckland 1640, New Zealand. 6 Horizon Radiology, Auckland University of Technology North Shore Campus, AA Building, 90 Akoranga Drive, Northcote, Auckland, New Zealand. 7 Auckland City Hospital Radiology, Auckland District Health Board, P.O. Box 92189, Auckland, New Zealand.

Received: 5 April 2017 Accepted: 15 May 2017

Published online: 22 May 2017

References
1. Stewart S, Dalbeth N, Vandal AC, Allen B, Miranda R, Rome K. Ultrasound features of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: comparison with normouricaemic individuals. Arthritis Care Res 2016 Published on 16 September 2016. doi:10.1002/acr.23082
2. Wright SA, Filippucci E, McVeigh C, Grey A, McCarron M, Grassi W, et al. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis. 2007;66:859–64.
3. Schneider-Weidemann C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol. 2007;62:437–43.
4. De Miguel E, Puig JC, Castillo MC, Rocha AL, Martinez MA, Torres RJ. Asymptomatic hyperuricaemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids. 2008;27:7592–5.
5. Stewart S, Dalbeth N, Vandal AC, Rome K. Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a cross-sectional observational study. J Foot Ankle Res. 2015;8:41–9.
6. Stewart S, Dalbeth N, Vandal AC, Rome K. Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricaemia: comparison with healthy individuals with normal serum urate concentrations. J Foot Ankle Res. 2016;9:1–9.
7. Stewart S, Morpeth T, Dalbeth N, Vandal AC, Carroll M, Davidtz L. Foot–related pain and disability and spatiotemporal parameters of gait during self-selected and fast walking speeds in people with gout: a two-arm cross sectional study. Gait Posture. 2015;44:18–22.
8. Rome K, Survepal D, Sanders A, Lobo M, McQueen FM, McNair P. Functional and biomechanical characteristics of foot disease in chronic gout: a case–control study. Clin Biomech. 2011;26:90–4.
9. Stewart S, Dalbeth N, Vandal AC, Rome K. The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2016;17:69–84.
10. Baker JF, Conaghan PG, Emery P, Baker DG, Ostergaard M. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. Ann Rheum Dis 2016 Published on 18 July 2016. doi: 10.1136/annrheumdis-2016-209463
11. Keen H, Redmond A, Wakefield R, Freeman J, Grainger AJ, Hensor EMA, et al. An ultrasonographic study of metatarsophalangeal joint pain: synovitis, structural pathology and their relationship to symptoms and function. Ann Rheum Dis. 2011;70:2140–3.
12. Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swearingen CJ, Samuels J. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res. 2011;63:1456–62.
13. Ottaviani S, Allard A, Bardin T, Richette P. An exploratory ultrasound study of early gout. Clin Exp Rheumatol. 2011;29:816–21.
14. Naredo E, Uson J, Jiménez-Palop M, Martínez A, Vicente E, Birota E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2013;72:1522–8.
15. Wallace SL, Robinson H, Masì AT, Decker J, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1997;40:895–900.
16. Martonelli C. Gain setting in power Doppler. Radiology. 1997;202:284–5.
17. Torp-Pedersen ST, Tenslev L. Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology. Ann Rheum Dis. 2008;67:143–9.
18. Gutiérrez M, Schmidt WA, Thiele RG, Keen H, Kaeley GS, Naredo E, et al. International consensus for ultrasound lesions in gout: Application to Delphi process and web-reliability exercise. Rheumatology (Oxford). 2015;54:1797–805.
19. Wakefield RJ, Balint PV, Sakdulare M, Filippucci E, Backhaus M, D’Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2003;30:2485–7.
20. Garrow AP, Papageorgiou AC, Silman AJ, Thomas E, Jayson MV, Macfarlane GJ. Development and validation of a questionnaire to assess disabling foot pain. Pain. 2000;85:107–13.
21. Hopson MM, McPoi T, Cornwall MM. Motion of the first metatarsophalangeal joint. Reliability and validity of four measurement techniques. J Am Podiatr Med Assoc. 1995;85:198.
22. Bohannon RW. Comfortable and maximum walking speed of adults aged 20–79 years: reference values and determinants. Age Ageing. 1997;26:198–204.
23. Boohannan BW. Knee and hip active and passive ranges of motion. J Orthop Sports Phys Ther. 1990;12:31–7.
24. Agostino MA, Dalbeth N, Vandal AC, Rome K. Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricaemia: comparison with healthy individuals with normal serum urate concentrations. J Foot Ankle Res. 2016;9:1–9.
25. Hoffmann J, Foot joint pain and disability and spatiotemporal parameters of gait during self-selected and fast walking speeds in people with gout: a two-arm cross sectional study. Gait Posture. 2015;44:18–22.
26. Wakefield RJ, Green MJ, Marzo-Ortega H, Conaghan PG, Gibbon WW, McGonagle D, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis. 2004;63:382–5.
30. Szkudlarek M, Narvestad E, Klarlund M, Cour-Payen M, Thomsen HS, Ostergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum. 2004;50:2103–12.

31. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958–67.

32. Ozgocmen S, Ozdemir H, Kiris A, Bozgeyik Z, Ardicoglu O. Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. South Med J. 2008;101:240–5.

33. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Beersden D, et al. 2015 gout classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67:2557–68.

34. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–4.

35. Roddy E, Zhang W, Doherty M. Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis. 2007;66:1374–7.